NASDAQ · ABSITechnologyR&D — Physical & Biological Sciences

Absci financials

$10.14+6.85%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$2.8M$4.5M$5.7M$5.7M$4.8M
Gross profit$2.8M$4.5M$5.7M$5.7M$4.8M
Gross margin100.0%100.0%100.0%100.0%100.0%
Operating income-$120.3M-$108.9M-$115.5M-$106.8M-$75.2M
Net income-$115.2M-$103.1M-$110.6M-$104.9M-$103.2M
Net margin−4113.7%−2274.1%−1933.6%−1825.4%−2159.0%
Diluted EPS$-0.84$-0.94$-1.20$-1.15$-2.08
EBITDA-$108.6M-$95.5M-$80.2M-$93.7M-$68.6M
Operating cash flow-$92.9M-$72.4M-$64.6M-$81.3M-$60.6M
Free cash flow-$94.0M-$72.8M-$65.5M-$97.5M-$98.6M
Diluted shares136.8M110.2M92.0M90.8M49.7M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$20.0M$41.2M$72.4M$60.0M$252.6M
Short-term investments$124.3M$71.2M$25.3M$104.5M$0.00
Total debt$873.0K$4.0M$8.6M$14.0M$9.5M
Total assets$216.3M$213.6M$217.3M$321.0M$426.2M
Total liabilities$26.8M$34.5M$41.1M$46.6M$60.1M
Shareholders' equity$189.4M$179.1M$176.2M$274.4M$366.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology